In this episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, has an in-depth discussion with Eric A. Adams, the CEO of InMed Pharmaceuticals, the Canada-based biopharmaceutical company focused on maximizing the therapeutic potential of cannabinoids. Max and Eric discuss Cannabinol (CBN), the minor cannabinoid at the heart of InMed’s programs, why the company chose it and the advantages it may have over cannabiodiol (CBD) and tetrahydrocannabinol (THC).
Conference Presentation – InMed Presents at Life Sciences Forum December 11, 2025
In this update on InMed Pharmaceuticals, CEO Eric A. Adams talks about the company’s Alzheimer’s disease program. Mr. Adams talks about the role of inflammation
January 12, 2026
